Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan;81(1):110-113.
doi: 10.1053/j.ajkd.2022.09.004. Epub 2022 Sep 17.

Cannabinoid Signaling in the Diabetic Proximal Tubule: Of Mice and Men

Abhijit S Naik  1 , Frank C Brosius  2
Affiliations
Editorial

Cannabinoid Signaling in the Diabetic Proximal Tubule: Of Mice and Men

Abhijit S Naik et al. Am J Kidney Dis. 2023 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proximal tubule (PT) cells and diabetic kidney disease (DKD). (A) Schematic of glucose transporters in the initial segments of the kidney PT. SGLT2 transports glucose from the PT lumen into the cytoplasm against its concentration gradient owing to the energetically favorable electrochemical gradient for sodium. The reabsorbed glucose is largely transported out of the cell down its concentration gradient by GLUT2, a high-capacity facilitative glucose transporter found on the basolateral surface. Relatively small numbers of GLUT2 molecules can be found on the luminal (apical) surface of the PT cells, where they transport glucose down its concentration gradient either in or out of the cell. Under usual physiologic conditions such transport would be out of the cell, since SGLT2 action increases glucose concentrations inside the cell relative to the concentration in the lumen, which falls substantially along the length of the proximal tubule. (B) Comparison between the cell-specific transcript expression of CNR1 (transcript coding for CB1R) and SLC5A2 (SGLT2) in PT cells from healthy controls (n = 18; 4,100 cells; left panel) or patients with DKD (n = 12; 5,300 cells; right panel). Data for healthy controls were adapted from Menon et al while data for the patients with DKD were from the Kidney Precision Medicine Project and obtained from Lake et al. At the protein level, CB1R is not detectable in glomeruli and tubules in human kidneys (sample image from Human Protein Atlas, available at www.proteinatlas.org/ENSG00000118432-CNR1/tissue/kidney#img).
See this image and copyright information in PMC

References

    1. Heerspink HJ, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. - PubMed
    1. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. - PubMed
    1. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. - PubMed
    1. Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121(6):2181–2196. - PMC - PubMed
    1. Gödel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011;121(6):2197–2209. - PMC - PubMed

Publication types